Wilfried Pott Ozgür Albayrak Anke Hinney Johannes Hebebrand Ursula Pauli-Pott
10.1159/000348792
Obes Facts
2013;6(1):109-15.
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/23493066/
Adrenergic Uptake Inhibitors / therapeutic use Attention Deficit Disorder with Hyperactivity / drug therapy Obesity / drug therapy Propylamines / therapeutic use Receptor, Melanocortin, Type 4 / metabolism
Adrenergic Uptake Inhibitors / therapeutic use Attention Deficit Disorder with Hyperactivity / drug therapy Obesity / drug therapy Propylamines / therapeutic use Receptor, Melanocortin, Type 4 / metabolism Case Reports Research Support, Non-U.S. Gov't Adolescent Atomoxetine Hydrochloride Attention Deficit Disorder with Hyperactivity / complications Attention Deficit Disorder with Hyperactivity / diagnosis Attention Deficit Disorder with Hyperactivity / genetics Attention Deficit Disorder with Hyperactivity / metabolism DNA Mutational Analysis Genetic Predisposition to Disease Humans Male Mutation Obesity / complications Obesity / diagnosis Obesity / genetics Obesity / metabolism Phenotype Receptor, Melanocortin, Type 4 / genetics Risk Reduction Behavior Treatment Outcome Weight Loss / drug effects Adrenergic Uptake Inhibitors MC4R protein, human Propylamines Receptor, Melanocortin, Type 4 Atomoxetine Hydrochloride
PMC5644743
23493066
Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function
2013